Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claim matches the FDA label indication wording for TAVNEOS adjunctive use in severe active ANCA-associated vasculitis in combination with standard therapy including glucocorticoids, and accurately includes that TAVNEOS does not eliminate glucocorticoid use.
Category Scores
Accurate Statements
TAVNEOS is indicated as adjunctive treatment of severe active ANCA-associated vasculitis with standard therapy including glucocorticoids.
Section 1 INDICATIONS AND USAGE: “TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.”
TAVNEOS does not eliminate glucocorticoid use.
Section 1 INDICATIONS AND USAGE: “… TAVNEOS does not eliminate glucocorticoid use.”
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The response only addresses an FDA-approved indication statement and does not provide dosing, safety, or monitoring instructions beyond what is necessary for indication alignment.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement